NCT00809848

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 172 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution in comparison with AGN-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or primary open-angle glaucoma. Subjects will be followed for 2 weeks.

Conditions

• Ocular Hypertension
• Glaucoma

Interventions

Type	Name	Description
DRUG	AGN-210669 ophthalmic solution, 0.075%	AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
DRUG	AGN-210669 ophthalmic solution, 0.05%	AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
DRUG	AGN-210669 ophthalmic solution, 0.025%	AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
DRUG	bimatoprost ophthalmic solution 0.03%	Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
DRUG	AGN-210669 vehicle ophthalmic solution	AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.

Timeline

• Start date: 2009-02-01
• Primary completion: 2009-05-01
• Completion: 2009-05-01
• First posted: 2008-12-17
• Last updated: 2013-10-18
• Results posted: 2013-10-18

Locations

1 site across 1 country: United States